作者彙整:hugoiis

Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption(N Engl J Med 2019; 380:1535-1545)

Administration of a single broadly neutralizing human immunodeficiency virus (HIV)–specific antibody to HIV-infected persons leads to the development of antibody-resistant virus in the absence of antiretroviral therapy (ART). It is possible that monotherapy with UB-421, an antibody that blocks the virus-binding site on human CD4+ T cells, could induce sustained virologic suppression without induction of resistance in HIV-infected persons after analytic treatment interruption. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

美國時代雜誌對新英格蘭醫學期刊4月18日週刊發表之聯生藥UB-421突破性愛滋病臨床試驗結果相關報導

HIV treatment has come a long way since the early days of the epidemic. Patients can now take various combinations of dozens of medications keep the virus under control and halt their disease from decimating their immune systems and leading to more serious, often fatal outcomes.

But harnessing HIV requires daily vigilance. Missing doses of the pills can give the virus the chance to develop resistance to the drugs and lead to a surge in new copies of HIV that flood the body.

In a new study published in the New England Journal of Medicine, researchers at Taiwan-based United BioPharma report encouraging results with a single injection that seems to stymie HIV as well as daily pill regimens. The results add to a growing number of studies suggesting that patients may be able to take pill holidays without putting their health at risk. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

Novel antibody may suppress HIV for up to four months(NIH News Releases)

Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online today in The New England Journal of Medicine. Results of the Phase 2, open-label study indicate the antibody, known as UB-421, was safe and did not induce the production of antibody-resistant HIV. The study was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, and United Biopharma, Inc. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine

United BioPharma Announces Publication of Breakthrough HIV Clinical

Trial Data in the New England Journal of Medicine 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥治療愛滋病抗體新藥 UB-421 臨床 II 期試驗結果 榮獲刊登於新英格蘭醫學期刊

聯合生物製藥(股)公司(聯生藥)今日宣布,其治療 HIV 感染之抗體新藥 UB-421
之臨床 II 期試驗結果以「Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound
after Treatment Interruption」為題的原創論文,榮獲刊登於最新一期的新英格
蘭醫學期刊(The New England Journal of Medicine, NEJM)。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

UB-421 Q & A

UB-421 Q & A 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

Introduction to UBP Chairwoman Dr. Wang ChangYi

United BioPharma (UBP), a spinoff company of UBI Asia, was founded by Dr. Chang Yi Wang. Dr. Wang serves as the executive Chairwoman of the Board of Directors and Chief Scientific Officer of UBP. At the invitation of the Taiwanese government in 1998, Dr. Wang set out to establish UBI-Asia, a joint venture between United Biomedical, Inc. (UBI) based in the US and the Taiwan government. She launched a state-of-the-art protein and antibody drug development platform within UBI Asia employing monoclonal antibody B4 as a touch stone and built a competent team with integrated platform technologies to enable development of antibody products from DNA to BLA filings. Other antibody and long acting protein products followed, leading to the spinoff of United Biopharma with a group of rigorously selected antibody products. 繼續閱讀

發表於 人物側寫, 專家筆記, 王長怡博士演講 | 發表迴響

數字台灣HD250 東協發展 越南新機會 謝金河 丁廣欽 羅子文

數字台灣HD250 東協發展 越南新機會 謝金河 丁廣欽 羅子文 繼續閱讀

發表於 政治觀察, 社會經濟 | 發表迴響

台灣之光 — 林詠晴教練! 波士頓馬拉松 台灣選手不畏風雨舉國旗衝線

台灣之光!林詠晴教練在陰雨、太陽及刮大風雨冰冷的多變的天氣下、勇敢的帶著青天白日國旗跑完2019 Boston Marathon!
繼續閱讀

發表於 社會經濟 | 發表迴響

《老謝看世界》20190413當景氣與債務周期雙雙下滑 全球打寒顫!? 謝金河 梁國源

《老謝看世界》20190413當景氣與債務周期雙雙下滑 全球打寒顫!? 謝金河 梁國源 繼續閱讀

發表於 政治觀察, 社會經濟 | 發表迴響

洪蘭教授:老人別當三等公民!

洪蘭教授:老人別當三等公民! 繼續閱讀

發表於 社會經濟 | 發表迴響

FOLLOWING JESUS

What makes someone a follower of Jesus? Going to church? Donating money to good causes? Trying to be a good person? The answer is actually much simpler: all we have to do is follow the Leader. In this message, Dr. Stanley outlines exactly how to walk in the footsteps of Jesus, surrendering our lives and mirroring His life of prayer, service, and sacrifice. 繼續閱讀

發表於 歷史軼聞, 社會經濟 | 發表迴響

聖經鳥瞰34 以弗所書(四)(王生台弟兄)

聖經鳥瞰34 以弗所書(四)(王生台弟兄) 繼續閱讀

發表於 社會經濟 | 發表迴響

一窺生命的源頭!古老尼羅河從氾濫到重生 “神獸"變民眾愛的萌寵【消失的國界】

一窺生命的源頭!古老尼羅河從氾濫到重生 “神獸"變民眾愛的萌寵【消失的國界】 繼續閱讀

發表於 社會經濟 | 發表迴響

數字台灣HD249 遊戲產業新方向 謝金河 王俊博 歐陽志宏

數字台灣HD249 遊戲產業新方向 謝金河 王俊博 歐陽志宏
繼續閱讀

發表於 政治觀察, 社會經濟 | 發表迴響